Société Générale — M&A Activity 2020

Apr 23, 2020

National Storage Mechanism | Additional information

RNS Number : 6294K

Societe Generale SA

23 April 2020

Ap19

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1.       KEY INFORMATION

Name of person dealing (Note 1)	Société Générale S.A.
Company dealt in	Allergan plc
Class of relevant security to which the dealings being disclosed relate (Note 2)	US$0.0001 ordinary shares
Date of dealing	22/04/2020

2.         INTERESTS AND SHORT POSITIONS

(a)        Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

	Long		Short
Number	(%)	Number	(%)
(1) Relevant securities	3,560,442	1.08	44,582	0.01
(2) Derivatives (other than options)	0	0.00	3,273,513	0.99
(3) Options and agreements to purchase/sell	58,500	0.02	0	0.00
Total	*7,675,902	*2.33	3,318,095	1.01

* Include the holding of 4,056,960 shares on borrow products

(b)        Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total

Ap20

1.       DEALINGS (Note 4)

(a)      Purchases and sales

Purchase/sale	Number of relevant securities	Price per unit USD (Note 5)
Purchase	200	185.34
Purchase	99	186.18
Purchase	1	186.18
Purchase	100	186.1
Purchase	100	186.02
Purchase	100	186.17
Purchase	11	186.23
Purchase	89	186.23
Purchase	100	185.88
Purchase	31	186.03
Purchase	100	185.89
Purchase	100	186.16
Purchase	100	186.05
Purchase	100	186.25
Purchase	100	186.34
Purchase	100	186.02
Purchase	100	186.17
Purchase	2	185.56
Purchase	576,600	185.34
Purchase	100	185.81
Purchase	300	185.34
Purchase	100	186.2
Purchase	100	186.06
Purchase	100	186.17
Purchase	100	186.3
Purchase	2,069	185.34
Purchase	100	185.76
Purchase	100	186.14
Purchase	4,938	185.34
Purchase	20	186.21
Purchase	600	185.34
Purchase	200	185.92
Purchase	100	185.71
Purchase	1,689	185.5802
Purchase	2,955	185.34
Sale	100	185.575
Sale	100	186.16
Sale	100	185.54
Sale	100	185.53
Sale	50	185.83
Sale	50	185.83
Sale	100	185.63
Sale	100	185.82
Sale	100	185.54
Sale	50	185.82
Sale	50	185.82
Sale	100	185.41
Sale	100	185.68
Sale	100	185.86
Sale	100	185.37
Sale	100	185.56
Sale	100	185.575
Sale	100	185.33
Sale	100	185.87
Sale	100	185.79
Sale	100	185.68
Sale	100	185.61
Sale	100	185.26
Sale	100	185.86
Sale	100	185.54
Sale	100	185.53
Sale	100	185.76
Sale	44	185.8
Sale	28	185.8
Sale	1	185.8
Sale	100	185.61
Sale	100	185.42
Sale	50	185.45
Sale	50	185.45
Sale	100	185.51
Sale	100	185.55
Sale	100	186.27
Sale	100	185.36
Sale	100	185.75
Sale	56	186.23
Sale	44	186.23
Sale	91	185.57
Sale	9	185.57
Sale	100	185.41
Sale	100	185.65
Sale	11	185.22
Sale	100	185.61
Sale	100	185.7
Sale	100	185.47
Sale	100	185.47
Sale	5	185.45
Sale	600	185.375767
Sale	2	185.34
Sale	200	185.56
Sale	76	185.34
Sale	124	185.330968
Sale	100	185.2
Sale	11	185.2
Sale	12	185.21
Sale	100	185.28
Sale	100	185.31
Sale	100	185.6
Sale	100	185.54
Sale	11	185.52
Sale	11	185.52
Sale	11	185.44
Sale	100	185.46
Sale	51	185.39
Sale	52	185.38
Sale	76	185.55
Sale	20	186.28
Sale	100	185.79
Sale	100	186.36
Sale	100	185.62
Sale	100	185.8
Sale	100	185.23
Sale	100	185.51
Sale	100	185.67
Sale	100	185.62
Sale	253	185.513241
Sale	72	185.263333
Sale	6	185.78
Sale	44	185.78
Sale	50	185.78
Sale	100	185.67
Sale	100	185.84
Sale	4	185.52
Sale	96	185.52
Sale	100	185.75
Sale	100	185.53
Sale	100	185.3
Sale	100	185.38
Sale	100	185.53
Sale	100	185.37
Sale	100	185.81
Sale	100	185.83
Sale	100	185.36
Sale	19	185.630632
Total Purchases	591,704
Total Sales	8,490

(b)      Derivatives transactions (other than options transactions)

Product name, e.g. CFD	Nature of transaction (Note 6)	Number of relevant securities (Note 7)	Price per unit USD (Note 5)
Equity Linked Swap	Increased short	576,600	185.34

(c)      Options transactions in respect of existing relevant securities

(i)       Writing, selling, purchasing or varying

Product name, e.g. call option	Writing, selling, purchasing, varying etc.	Number of securities to which the option relates (Note 7)	Exercise price	Type, e.g. American, European etc.	Expiry date	Option money paid/received per unit (Note 5)

(ii)      Exercising

Product name, e.g. call option	Number of securities	Exercise price per unit (Note 5)

(d)      Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction (Note 8)	Details	Price per unit (if applicable) (Note 5)

Ap21

2.       OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the 

voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition 

or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

Is a Supplemental Form 8 attached? (Note 9)                                            Yes

Date of disclosure	23/04/2020
Contact name	Société Générale - Disclosure team
Telephone number	+33 1 42 14 92 74
If a connected EFM, name of offeree/offeror with which connected
If a connected EFM, state nature of connection (Note 10)

Ap23

SUPPLEMENTAL FORM 8

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1 AND RULE 8.3 OF THE IRISH TAKEOVER PANEL 

ACT, 1997, TAKEOVER RULES, 2013

DETAILS OF OPEN POSITIONS

(This form should be attached to Form 8.1(a) & (b)(i), Form 8.1(b)(ii) or Form 8.3, as appropriate)

OPEN POSITIONS (Note 1)

Product name, e.g. call option	Written, or purchased	Number of relevant securities to which the option or derivative relates	Exercise price (Note 2)	Type, e.g. American, European etc.	Expiry date
Listed Put Option	Sale	40,000	175	American options	15/01/2021
Listed Put Option	Sale	18,500	190	American options	15/01/2021

Notes

1.          Where there are open option positions or open derivative positions (except for CFDs), full details should be given. 

Full details of any existing agreements to purchase or to sell must also be given on this form.

2.          For all prices and other monetary amounts, the currency must be stated.

For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

ISESEUSWDESSESL